PKS Advisory Services LLC Makes New Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

PKS Advisory Services LLC purchased a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the fourth quarter, Holdings Channel reports. The fund purchased 17,650 shares of the company’s stock, valued at approximately $63,000.

Other institutional investors and hedge funds have also modified their holdings of the company. New York State Common Retirement Fund raised its holdings in Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $43,000 after buying an additional 10,700 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Aquestive Therapeutics during the 4th quarter valued at about $69,000. Intech Investment Management LLC bought a new position in shares of Aquestive Therapeutics in the 3rd quarter valued at approximately $90,000. BNP Paribas Financial Markets lifted its holdings in Aquestive Therapeutics by 252.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after purchasing an additional 13,481 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in Aquestive Therapeutics during the fourth quarter worth approximately $115,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Performance

Shares of AQST opened at $3.12 on Thursday. Aquestive Therapeutics, Inc. has a 52 week low of $2.24 and a 52 week high of $5.80. The firm has a market capitalization of $308.48 million, a P/E ratio of -6.93 and a beta of 2.76. The company has a 50-day simple moving average of $2.99 and a 200-day simple moving average of $3.97.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $13.11 million. As a group, equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on AQST shares. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Monday, March 10th. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research report on Friday, March 7th. Finally, Lake Street Capital lowered their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $10.57.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.